Aldioxa: CIR Safety Assessment Summary
CIR safety assessment summary for Aldioxa: ingredients reviewed, panel verdict, use concentration context, conditions, and source citation.
Aldioxa appears in a CIR safety assessment covering Aldioxa. The panel verdict for the report is insufficient data. The safety of Aldioxa has not been documented and substantiated. The CIR Expert Panel cannot conclude that this ingredient is safe for use in cosmetic products until the appropriate safety data have been obtained and evaluated.
| Field | CIR value |
|---|---|
| Primary ingredient | Aldioxa |
| CIR verdict | insufficient data |
| Report type | Final Report |
| Date | 1993 |
| CAS numbers | 5579-81-7 |
| Conditions or carve-outs | The safety of Aldioxa has not been documented and substantiated. |
Ingredients Reviewed
The review scope matters because CIR conclusions often apply to an ingredient family rather than a single INCI name. In this report, the ingredient list includes Aldioxa.
Safety Conclusion
The conclusion for Aldioxa should be read as a CIR panel conclusion, not a regulatory limit. CIR assessments summarize expert-panel safety determinations for cosmetic use, while legal status still depends on the jurisdiction and product category.
Conditions
The safety of Aldioxa has not been documented and substantiated.
Formulation Reading
For formula review, begin with the exact INCI identity and the ingredient group covered by the CIR assessment. If the material is Aldioxa, the relevant comparison is whether the intended use aligns with the practices, concentration ranges, and conditions described in the CIR source.
The ingredient hub at Aldioxa should carry the substance-level profile. This page is the report-level summary, keeping the conclusion, ingredient scope, and use-context language attached to the CIR source rather than treating the conclusion as a universal permission.
Why This Page Exists
CIR reviews are long documents, and the practical answer is usually buried in the conclusion and the table of current practices. This summary keeps those CIR facts in one indexable page for Aldioxa, with source details retained at the bottom for audit.
Review Notes
The conservative reading is to keep Aldioxa tied to the exact CIR report listed below. The ingredient family, panel conclusion, date, and any use-condition language belong together. A shorter ingredient-page snippet would lose that context.
This page gives the search-level answer while preserving the source-level caveat: CIR safety language is a panel assessment for cosmetic practices of use, not a universal legal permission across every jurisdiction or product category.
The source section is intentionally specific. It keeps Aldioxa connected to the CIR report file and conclusion page so the summary remains an audit-friendly report page instead of a loose ingredient claim.
The page also preserves the internal ingredient link and report source together, which keeps Aldioxa connected to both the substance profile and the CIR record.
Source
- CIR report: Final Report on the Safety Assessment of Aldioxa
- CIR source file: pr94.pdf
- Extraction JSON: Source documentation archived.
- Conclusion page in CIR extraction: 5